PHOENIX, April 12, 2022 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial-stage biotechnology company focused on a regenerative approach to immunotherapy, of Urology, Neurology and Orthopedics, today announced that she will be exhibiting at the American Urological Association (“AUA”) Annual Meeting on May 13-16, 2022 in New Orleans to introduce CaverStem®, the only patented procedure performed by a licensed physician that provides a safe and effective solution to treat erectile dysfunction by using the patient’s own stem cells to repair damaged tissue.
“With the addition of team members with decades of experience in medicine and medical marketing, we are excited to introduce CaverStem® to this very important group of practicing physicians. CaverStem® is backed by trial results clinical trials published in a peer-reviewed journal and backed by patient testimonials who have had positive, life-changing results,” said Timothy WarbingtonPresident and CEO of Creative Medical Technology.
- Landmark clinical trial results published in Journal of Translational Medicine demonstrating strong efficacy and no major adverse effects (Link)
- Protocol optimized to eliminate the need for a centrifuge – reducing equipment costs and streamlining the procedure for providers and patients
- Exclusive rights for the use of the device approved by the FDA
- Expansion of the physician network – validating not just the technology, but the lucrative business model
- Optimized consumer awareness programs to support healthcare providers in raising awareness
The company’s speakers at the conference will include Dr. Naveen Kella of the place of urology (www.TheUrologyPlace.com), who has successfully performed more than 50 procedures in his San Antonio, TX location. Dr. Kella will share his experience of the ongoing support training he receives from Creative Medical Technology and the impact it has had on his practice and his patients.
“We first read the study on CaverStem® and after talking to other providers we were encouraged by this technology. I am delighted to present my own experience with this treatment for which we collect data on the results,” Dr. Kella said.
The company plans to use the AUA event to share updated data on CaverStem and recruit additional vendors.
Interested in becoming a supplier:
You don’t have to wait for the conference to start to get started as a provider. To get started, simply complete the form here: https://caverstem.com/become-a-provider/.
About Dr. Naveen Kella:
Dr. Naveen Kella is board certified in urology, with a fellowship in urological oncology and robotic surgery. He is known for his experience in treating prostate cancer and has performed over 3,000 robotic prostate cancer surgeries. He has a keen interest in finding ways to continually minimize the side effects of treatments.
About erectile dysfunction:
Erectile dysfunction (ED) is characterized by the lack of ability to achieve and maintain a penile erection for sexual intercourse. Methods used to quantify erectile dysfunction include the Visual Analogue Scale of Erectile Function (EF-VAS) and the International Index of Erectile Function (IIEF-5), but clinically it is primarily diagnosed based on symptomatology . In our aging society, erectile dysfunction is becoming a growing problem. According to one study, 39% of men at age 40 show symptoms of erectile dysfunction, while at age 70 the incidence rises to 67%. In this latter age group, 50-85% of erectile dysfunction cases are believed to be associated with hypertension, diabetes, cardiovascular disease and dyslipidemia. Overall, an estimated 10 to 30 million Americans suffer from this condition.
Creative Medical Technology Holdings, Inc. is a commercial-stage biotechnology company specializing in regenerative medicine in the areas of immunotherapy, urology, neurology and orthopedics. For more information about the company, please visit www.creativemedicaltechnology.com.
This press release may contain forward-looking statements, including, but not limited to, comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements relate to future events and conditions and, therefore, involve risks and uncertainties. Actual results may differ materially from those currently anticipated in these statements. See periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at www.sec.gov.
SOURCE Creative Medical Technology Holdings, Inc.